How important is this statement. L1 Capital has completed, (SIGNIFICANT DUE DILIGENCE VIA THEIR SPECIALIST MEDICAL CONSULTANT)
PRIOR TO EXECUTING THE PLACEMENT AGREEMENT.
They have confidence in what CHM have, simple as that.
Chimeric’s Executive Chairman Paul Hopper said: “We are delighted to have the support of a
leading fund manager like L1 Capital, with a strong interest in life science investing. L1’s
commitment is testament to the quality of the Company’s clinical assets, having completed
significant due diligence via their specialist medical consultant based in Israel prior to executing
the placement agreement.
How important is this statement. L1 Capital has completed,...
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.18M | |||
| Open | High | Low | Value | Volume |
| 1.6¢ | 1.7¢ | 1.6¢ | $2.101K | 127.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 1919476 | 1.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.7¢ | 328619 | 3 |
View Market Depth
| Last trade - 15.32pm 29/08/2024 (20 minute delay) ? |
| CHM (ASX) Chart |